|
About Multimeric Biotherapeutics
Multimeric Biotherapeutics ("Multimeric") is an early-stage, product-oriented biotech company based on a technology for expressing TNF superfamily (TNFSF) molecules as multimeric, many-trimer soluble proteins with markedly enhanced activity. Molecules with 4 TNFSF trimers are called the "UltraLigands™" and molecules with 2 TNFSF trimers are called the "MegaLigands™." The lead compound is UltraCD40L™ (SP-D-CD40L), a 4-trimer form of CD40 ligand (CD40L) that very strongly stimulates the immune system. A similar protein, MegaCD40L™ (Acrp30-CD40L), is a 2-trimer molecule that is already in use by research laboratories around the world as a powerful immune stimulating agent. Multimeric has exclusive worldwide licenses to the therapeutic uses of the TNFSF multimerization technology, which can also be applied to the other 18 proteins in the TNF superfamily for use in cancer immunotherapy, vaccines, transplantation, and regenerative medicine. For its first clinical trial, Multimeric is planning a breakthrough cancer treatment that combines genetic information obtained from a patient's own tumor cells with an UltraCD40L™-enabled strategy that generates anti-tumor T lymphocytes for administration back into the patient's body to fight the tumor.
|